Long-term combination therapy with Metformin and Oxymetholone in a Fanconi Anemia mouse model.

ABSTRACT: Fanconi Anemia (FA) is a disease caused by defective DNA repair which manifests as bone marrow failure, cancer predisposition, and developmental defects. Mice containing inactivating mutations in one or more genes in the FA pathway partially mimic the human disease. We previously reported that monotherapy with either metformin (MET) or oxymetholone (OXM) improved peripheral blood (PB) counts and the number and functionality of bone marrow (BM) hematopoietic stem progenitor cells (HSPCs) number in Fancd2^-/- mice. To evaluate whether the combination treatment of these drugs has a synergistic effect to prevent bone marrow failure in FA, we treated cohorts of Fancd2^-/- mice and wild-type controls with either MET alone, OXM alone, MET+OXM or placebo diet. Bot

SUBMITTER: Dorrell C 

PROVIDER: S-EPMC10465065 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature